Noticias

Noticias

  • Título: Japanese Postmarket Surveillance Data for Zilver PTX Presented at EuroPCR 2014
  • Fecha: 29-05-2014

  • BLOOMINGTON, Ind.--()--One-year follow-updata from 907 Japanese patients who received the Zilver® PTX® drug-eluting stent showed positive results inkeeping open the superficial femoral artery (SFA). The postmarket surveillance(PMS) study, designed to evaluate the stent’s performance in real-world patientuse, was presented at the 2014 Euro PCR meeting.

    The PMS study wasbased in Japan and presented by Hiroyoshi Yokoi, M.D. of Fukuoka SannoHospital. It included 907 patients with peripheral arterial disease (PAD)treated with Zilver PTX. Of those, 838 were eligible for 12-month follow up.After one year, 91.4 percent of the patients in the follow-up group did notneed target lesion revascularization (TLR) of the SFA. The 84.8 percent primarypatency result in the PMS study is similar to results from earlier Zilver PTXstudies1.

    “We’re very pleasedwith the data from the Japan PMS study because the study included a broad rangeof lesion types and lengths similar to what doctors treat on a daily basis.Like our other studies, this evaluation shows that for most patients there isan enduring drug effect from Zilver PTX a year after implantation,” said MarkBreedlove, global leader for Cook Medical’s Peripheral Interventional (PI)division.

    Zilver PTX has beenapproved for use in the European Union since August 2009 and the United States and Japan since 2012. Since its release, the stent has been used to treat morethan 25,000 patients in North America, Europe, Asia, South America, Australia and New Zealand.



  • Fuente: endovascular.es